← Retour au Screener

Sector: Santé
Open in Terminal → PSNLLive chart · Key metrics · News · Smart money

Personalis

PSNL Small Cap

Healthcare · Diagnostics & Research

Mis à jour: Jun 18, 2026, 22:21 UTC

9,20 €
+8.1% aujourd'hui
52W: 3,35 € – 10,93 €
52W Low: 3,35 € Position: 77.1% 52W High: 10,93 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
17.11x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
963 M €
Capitalisation boursière
Croissance du CA
-24.9%
Croissance du CA sur un an
Marge bénéficiaire
-148.11%
Marge nette
ROE
-41.35%
Rentabilité des capitaux propres
Beta
2.28
Sensibilité au marché
Positions vendeuses
19.34%
% du flottant vendu à découvert
Volume moyen
2,376,392
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
None
7 analysts
Avg. Price Target
9,48 €
+3.01% upside
Target Range
7,85 € – 11,34 €

About the Company

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 259 Exchange: NGM

Personalis en bref

Personalis (PSNL) is currently trading at 9,20 € with a market capitalization of 963 M €. The 52-week range spans from 3,35 € to 10,93 €; the current price is 15.9% below the yearly high. Year-over-year revenue growth stands at -24.9%.

💰 Dividende

Personalis currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent Personalis (PSNL) au consensus : None. L'objectif de cours moyen est de 9,48 €, soit un potentiel de +3.01% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 7,85 € à 11,34 €.

Personalis : la thèse d'investissement en détail

Personalis (PSNL) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -24.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 2.28, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.

Thèse d'investissement : forces et faiblesses

Points forts
  • Bilan solide avec faible endettement (D/E 15.22)
Points faibles
  • CA en contraction (-24.9% sur un an)
  • Actuellement non rentable
  • Forte volatilité (Bêta 2.28)
  • Positions vendeuses élevées (19.34%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
6,70 €
+37.24% vs. cours
MM 200 jours
7,01 €
+31.26% vs. cours
Sous le plus haut 52s
−15.9%
10,93 €
Au-dessus du plus bas 52s
+174.5%
3,35 €

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

Risque de marché (Bêta)
2.28 · Élevé
Évolue plus que le marché global
Positions vendeuses
19.34% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
15.22 · Faible
Dette totale / capitaux propres

The data points to above-average price swings, elevated short interest (19.34%).

Trading Data

50-Day MA: 6,70 €
200-Day MA: 7,01 €
Volume: 3,308,737
Avg. Volume: 2,376,392
Short Ratio: 4.52
P/B Ratio: 4.33x
Debt/Equity: 15.22x
Free Cash Flow: -36 960 663 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Personalis?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut